

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.

Amniotics procures top guarantee commitments and enters into additional subscription undertakings for a fully secured rights issue

On August 31, 2023, the Board of Directors of Amniotics AB (publ) (“Amniotics” or the “Company”) resolved, subject to subsequent approval at the extraordinary general meeting in the Company on October 3, 2023, to carry out an issue of units consisting of shares and warrants with preferential rights for the Company’s existing shareholders of approximately SEK 25 million (the “Rights Issue”). Amniotics hereby announces that the Company has secured a top guarantee syndicate, consisting of, among others, Max Mitteregger and the Company’s board member Fredrik Tiberg, in addition to the previously announced guarantee syndicate. The top guarantee syndicate has provided top guarantees of in total SEK 5 million, corresponding to approximately 20 percent of the Rights Issue. Furthermore, the Company has previously communicated that the Company’s CEO and board member Marcus Larsson, via Deflexum AB, Chairman of the Board Peter Buhl Jensen and board members Ingrid Atteryd Heiman and Fredrik Tiberg, have given subscription intentions of in total approximately SEK 3.0 million, corresponding to approximately 11.9 percent of the Rights Issue. Amniotics hereby announces that those who have given subscription intentions have now, through subscription undertakings, formally undertaken to subscribe for units in the Rights Issue. The Rights Issue is thus covered by subscription undertakings, bottom and top guarantee commitments amounting to approximately SEK 25 million, corresponding to 100 percent of the Rights Issue. Hence, the Rights Issue is now fully secured.

In addition to the previously communicated guarantee commitments, Amniotics has secured a top guarantee syndicate, consisting of, among others, Max Mitteregger and the Company’s board member Fredrik Tiberg, for a total of SEK 5 million, corresponding to approximately 20 percent of the Rights Issue. For the top guarantee commitments, cash guarantee compensation of sixteen (16) percent of the guaranteed amount is paid.

Furthermore, the Company has previously announced that the Company’s CEO and board member Marcus Larsson, via Deflexum AB, Chairman of the board Peter Buhl Jensen and board members Ingrid Atteryd Heiman and Fredrik Tiberg, have given subscription intentions of in total approximately SEK 3.0 million, corresponding to approximately 11.9 percent of the Rights Issue. Since the announcement, the Company has now received formal subscription undertakings from all of those who previously communicated subscription intentions. Through the subscription undertakings, Deflexum AB has undertaken to subscribe for approximately SEK 2.5 million, Peter Buhl Jensen has

undertaken to subscribe for SEK 250 thousand, Ingrid Atteryd Heiman has undertaken to subscribe for SEK 10 thousand and Fredrik Tiberg has undertaken to subscribe for approximately SEK 194 thousand. No compensation is paid for subscription undertakings received.

The Rights Issue is thus covered by subscription undertakings of approximately SEK 6.5 million, bottom guarantee commitments of approximately SEK 13.5 million, and top guarantee commitments of SEK 5 million, which in summary means that the Rights Issue is secured to approximately SEK 25 million, corresponding to 100 percent of the Rights Issue. Hence, the Rights Issue is now fully secured.

Advisors

Redeye AB acts as financial advisor and Setterwalls Advokatbyrå AB acts as legal advisor to Amniotics in connection with the Rights Issue. Nordic Issuing acts as issuer agent in connection with the Rights Issue.

For more information, contact: Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

This information is information that Amniotics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 6 September 2023 [time] CEST.

About Amniotics Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now in clinical phase with the leading drug candidate PulmoStem™. The company is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

The company is listed at Nasdaq First North Growth Market in Stockholm.
Amniotics Certified Adviser at First North is Redeye AB, e-post: certifiedadviser@redeye.se.

Learn more at www.amniotics.com.

IMPORTANT INFORMATION

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in Amniotics. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for units in Amniotics will only be made through the Prospectus that Amniotics estimates to publish on 9 October 2023 on Amniotics's website, www.amniotics.com (the "**Prospectus**") The upcoming approval of the Prospectus by the Swedish Financial Supervisory Authority shall not be regarded as an approval of the shares, warrants or any other securities. This release is however not a prospectus in accordance with the definition in the Prospectus Regulation (EU) 2017/1129 ("**Prospectus Regulation**") and this announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in Amniotics. In order for investors to fully understand the potential risks and benefits associated with a decision to participate in the Rights Issue, any investment decision should only be made based on the information in the Prospectus. Thus, investors are encouraged to review the Prospectus in its entirety. In accordance with article 2 k of the Prospectus Regulation this press release constitutes an **advertisement**.

The information in this press release may not be released, distributed or published, directly or indirectly, in or into the United States of America, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea, Switzerland or any other jurisdiction in which such action would be unlawful or would require registration or any other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares, warrants or other securities in Amniotics have been registered, and no shares, warrants or other securities will be registered, under the United States Securities Act of 1933, as amended (the "**Securities Act**") or the securities legislation of any state or other jurisdiction in the United States of America and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States of America, except under an available exemption from, or in a transaction not subject to, the registration requirements under the Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States of America.

Within the European Economic Area ("**EEA**"), no public offering of shares, warrants or other securities ("**Securities**") is made in other countries than Sweden. In other member states of the EU, such an offering of Securities may only be made in accordance with the Prospectus Regulation. In other member states of the EEA which have implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure. In other member states of the EEA which have not implemented the Prospectus Regulation in its national legislation, any offer of Securities may only be made in accordance with an applicable exemption under national law.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are

(i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “**Order**”); (ii) high net worth entities etc. falling within Article 49 (2)(a) to (d) of the Order; or (iii) such other persons to whom such investment or investment activity may lawfully be made available under the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release may contain forward-looking statements which reflect the Company’s current view on future events and financial and operational development. Words such as “*intend*”, “*expect*”, “*anticipate*”, “*may*”, “*believe*”, “*plan*”, “*estimate*” and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.

Press Release
06 September 2023 13:59:00 CEST



This information is information that Amniotics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-09-06 13:59 CEST.

Attachments

Amniotics procures top guarantee commitments and enters into additional subscription undertakings for a fully secured rights issue